Fig. 1From: Metabolic and cardiorespiratory effects of decreasing lung hyperinflation with budesonide/formoterol in COPD: a randomized, double-crossover, placebo-controlled, multicenter trialSummary of (a) study design and (b) patient disposition. AEs, adverse events; BUD/FORM, budesonide/formoterol; COPD, chronic obstructive pulmonary disease; pMDI, pressurized metered-dose inhalerBack to article page